BACKGROUND: Serum free triiodothyronine (fT3) level is suggested to be a risk factor for mortality in unselected dialysis patients. We investigated the prognostic value of serum fT3 levels and also low-T3 syndrome on overall survival in a large cohort of hemodialysis (HD) patients with normal thyroid-stimulating hormone levels. METHODS: A total of 669 prevalent HD patients were enrolled in the study. Serum fT3 level was measured by enzyme immune assay in frozen sera samples at the time of enrollment. Overall mortality was assessed during 48 months of follow-up. RESULTS: Baseline fT3 was 1.47 ± 0.43 (0.01-2.98) pg/ml, and low-T3 syndrome was present in 71.7% of the cases. During a mean follow-up of 34 ± 16 months, 165 (24.7%) patients died. fT3 level was a strong predictor for mortality in crude and adjusted Cox models including albumin or high-sensitivity C-reactive protein (hs-CRP). Further adjustment for both albumin and hs-CRP made the impact of fT3 on mortality disappear. The presence of low-T3 syndrome was associated with mortality in only the unadjusted model. CONCLUSIONS: Low-T3 syndrome is a frequent finding among HD patients, but it does not predict outcome. However, serum fT3 level is a strong and inverse mortality predictor, in part explained by its underlying association with nutritional state and inflammation.
BACKGROUND: Serum free triiodothyronine (fT3) level is suggested to be a risk factor for mortality in unselected dialysis patients. We investigated the prognostic value of serum fT3 levels and also low-T3 syndrome on overall survival in a large cohort of hemodialysis (HD) patients with normal thyroid-stimulating hormone levels. METHODS: A total of 669 prevalent HDpatients were enrolled in the study. Serum fT3 level was measured by enzyme immune assay in frozen sera samples at the time of enrollment. Overall mortality was assessed during 48 months of follow-up. RESULTS: Baseline fT3 was 1.47 ± 0.43 (0.01-2.98) pg/ml, and low-T3 syndrome was present in 71.7% of the cases. During a mean follow-up of 34 ± 16 months, 165 (24.7%) patients died. fT3 level was a strong predictor for mortality in crude and adjusted Cox models including albumin or high-sensitivity C-reactive protein (hs-CRP). Further adjustment for both albumin and hs-CRP made the impact of fT3 on mortality disappear. The presence of low-T3 syndrome was associated with mortality in only the unadjusted model. CONCLUSIONS:Low-T3 syndrome is a frequent finding among HDpatients, but it does not predict outcome. However, serum fT3 level is a strong and inverse mortality predictor, in part explained by its underlying association with nutritional state and inflammation.
Authors: Erhan Tatar; Meltem Sezis Demirci; Fatih Kircelli; Ozkan Gungor; Mustafa Yaprak; Gulay Asci; Ali Basci; Mehmet Ozkahya; Ercan Ok Journal: Int Urol Nephrol Date: 2011-07-22 Impact factor: 2.370
Authors: Christiaan L Meuwese; Friedo W Dekker; Bengt Lindholm; Abdul R Qureshi; Olof Heimburger; Peter Barany; Peter Stenvinkel; Juan J Carrero Journal: Clin J Am Soc Nephrol Date: 2012-01 Impact factor: 8.237
Authors: Connie M Rhee; Gregory A Brent; Csaba P Kovesdy; Offie P Soldin; Danh Nguyen; Matthew J Budoff; Steven M Brunelli; Kamyar Kalantar-Zadeh Journal: Nephrol Dial Transplant Date: 2014-02-25 Impact factor: 5.992
Authors: Baris Afsar; Mahmut Ilker Yilmaz; Dimitrie Siriopol; Hilmi Umut Unal; Mutlu Saglam; Murat Karaman; Mustafa Gezer; Alper Sonmez; Tayfun Eyileten; Ibrahim Aydin; Salih Hamcan; Yusuf Oguz; Adrian Covic; Mehmet Kanbay Journal: J Nephrol Date: 2016-04-02 Impact factor: 3.902